Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: "biochemical recurrence" Clear all

Conditions: Prostate Cancer
Interventions: OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo; Drug · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Castration Sensitive Prostate Cancer
Interventions: Degarelix, Ipilimumab, Radical Prostatectomy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Cancer
Interventions: High Dose Brachytherapy, Stereostatic Body Radiation Therapy; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Prostate Adenocarcinoma
Interventions: CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT); Radiation · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Allergic Reaction (IgA) Vasculitis
Interventions: BBD-1 Multi target Immune Enhancement Targeting Agent; Drug
Lead sponsor: Qifeng Zhang; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: huJ591, 89Zr-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Proton beam; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions: metformin hydrochloride, placebo, Chemotherapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more

Conditions: Chronic Pancreatitis, Chronic Pain, Acute Recurrent Pancreatitis
Interventions: Quantitative Sensory Test 1, Quantitative Sensory Test 2, Quantitative Sensory Test 3; Diagnostic Test
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cushing Syndrome, Endocrine Disease
Interventions: Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG; Drug · Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uterine Cervical Neoplasms
Interventions: Zoledronic acid; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Revlimid; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
Interventions: 36.25 Gy IMRT, 51.6 Gy IMRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 25 more

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone, Healthy volunteers; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Butner, North Carolina

Conditions: Tobacco Use Disorder, Mental Illness, Recurring Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Persistent Depressive Disorder
Interventions: Quit on the Go App (formerly "Learn to Quit " App), Brief advice, Nicotine patch, Smartphone coaching, Nicotine gum, Nicotine Lozenges; Device · Behavioral · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Buffalo, New York • Durham, North Carolina • Winston-Salem, North Carolina

Conditions: Recurrent Prostate Cancer
Interventions: computed tomography, bone scan, 3-Tesla magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis; Procedure · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Duarte, California • South Pasadena, California

Conditions: Prostate Cancer
Interventions: Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, B-Cell
Interventions: Pralatrexate, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Beverly Hills, California • Post Falls, Idaho • Chicago, Illinois + 8 more

Conditions: Head and Neck Cancer
Interventions: IL-12; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hodgkin's Lymphoma
Interventions: Entinostat; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 3 more

Conditions: Prostatic Neoplasms
Interventions: HSV-tk with Valacyclovir & Brachytherapy; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: [11C]Acetate; Drug
Lead sponsor: Wendell Yap, MD; Other
Eligibility: 45 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prostate Cancer
Interventions: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Search by objective public record fields.

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis

Neoadjuvant J591 Treatment for Prostate Cancer

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Pancreatic Quantitative Sensory Testing (P-QST)

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

Radiation Therapy in Treating Patients With Prostate Cancer

Metabolic Signatures and Biomarkers in Schizophrenia

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT